Newsroom

Press Releases

 

AllianceRx Walgreens Prime study demonstrates favorable adherence, but high cost for cystic fibrosis patients prescribed modulator medications

Findings presented at Academy of Managed Care Pharmacists (AMCP) Nexus, ISPOR Europe conferences   ORLANDO, Fla. – Nov. 5, 2019 – AllianceRx Walgreens Prime and Duquesne University School of Pharmacy recently announced results from research analyzing data from cystic fibrosis (CF) patients prescribed cystic fibrosis transmembrane conductance regulator (CFTR) modulator medications.

Read More >

Media Contact

Adrienne Foley
Corporate Communications Manager
adrienne.foley@alliancerxwp.com

Connect with us 24/7